Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsFlorida Blue GLP-1 Prior Auth Coverage Update | Op…
    Ask Trek AI about this page
    ModifiedFlorida BluePolicy N/A

    providers-news-2023-pharmacy-glp-1-drugs-11-2023.pdf

    Customize your policy alerts

    Sign up for all Florida Blue policy alerts

    Know when Florida Blue releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Provider bulletin from Florida Blue describing pharmacy coverage and prior authorization requirements for the GLP-1 drug class for commercial and Medicare plans, limiting coverage to FDA‑approved indications for type 2 diabetes and excluding use for weight loss/management.

    Policy Summary
    PayerFlorida Blue
    Policyproviders-news-2023-pharmacy-glp-1-drugs-11-2023.pdf
    Policy CodePolicy N/A
    Change TypeCoverage & prior authorization criteria revised
    Effective Date
    Next Review Date
    Key ActionProviders must include clinical documentation of a type 2 diabetes diagnosis and document prior trial/failure of metformin/metformin combos or insulin with GLP‑1 prior authorization requests; requests lacking this documentation will be denied.
    SourceLink
    POLICY UPDATE CHANGES

    Commercial GLP‑1 prior authorization criteria were updated to require clinical documentation of type 2 diabetes diagnosis and documentation of prior trial/failure of metformin/metformin combinations or insulin.

    Florida Blue clarified that GLP‑1 coverage is limited to FDA‑approved indications for type 2 diabetes and that medications for weight loss/management are excluded.

    5Preferred GLP-1 agents listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    What changed — quick summary

    Florida Blue updated provider communications clarifying that GLP-1 class coverage is limited to FDA‑approved indications for type 2 diabetes; prior authorization requests for off‑label uses (including weight loss/management) will not be approved.

    Prime Therapeutics is Florida Blue's pharmacy benefits manager and will handle prior authorization requests; the updated criteria increase documentation requirements (clinical documentation of a type 2 diabetes diagnosis and prior trial/failure of metformin/metformin combinations or insulin), creating additional administrative burden and resulting in denials if required documentation is not provided.

    Summary
    Policyproviders-news-2023-pharmacy-glp-1-drugs-11-2023.pdf
    PayerFlorida Blue
    SubjectGLP-1 drugs prior authorization and coverage for type 2 diabetes
    Change typeMODIFIED
    Has material changeyes
    Effective date

    Coverage criteria and denial conditions

    Coverage criteria for GLP-1 drugs (commercial plans)

    Covered when ALL of the following are met:

    ALL of the following

    • FDA‑approved indication: Indication is an FDA‑approved indication related to treatment of type 2 diabetes (documented in clinical record).
    • Documented diagnosis: Provider submits clinical documentation of a type 2 diabetes diagnosis with the prior authorization request.
    • Prior therapy trial/failure: Documentation shows patient has tried and failed metformin, other metformin combination drugs, or insulin to demonstrate medical necessity for GLP‑1 approval.

    Not covered / will be denied

    Covered and excluded GLP‑1 drugs (examples)

    Preferred GLP-1 drugs covered for type 2 diabetes (commercial plans)mixedCovered
    MounjaroPreferred GLP-1 product listed by Florida Blue for type 2 diabetes
    RybelsusPreferred GLP-1 product listed by Florida Blue for type 2 diabetes
    OzempicPreferred GLP-1 product listed by Florida Blue for type 2 diabetes
    TrulicityPreferred GLP-1 product listed by Florida Blue for type 2 diabetes
    VictozaPreferred GLP-1 product listed by Florida Blue for type 2 diabetes
    Examples of excluded medications for weight loss/managementmixedNot Covered
    WegovyExcluded when used for weight loss/management
    SaxendaExcluded when used for weight loss/management

    What providers must do

    Prior Authorization

    Submit clinical documentation of type 2 diabetes

    Providers must include clinical documentation of a type 2 diabetes diagnosis with GLP‑1 prior authorization requests; requests lacking this documentation will be denied.

    Prior Authorization

    Document prior therapy trial/failure

    Providers must document that the patient has tried and failed metformin, metformin combination drugs, or insulin when requesting GLP‑1 coverage to demonstrate medical necessity; failure to do so will result in denial.

    Denial Risk

    Do not submit requests for weight loss/management

    Definitions and scope notes

    GLP-1: Glucagon-like Peptide 1 drug class.

    Applies to Florida Blue commercial and Medicare pharmacy plans; coverage is limited to FDA‑approved type 2 diabetes indications and explicitly excludes medications used for weight loss/management (requests for weight‑loss indications should not be submitted to Prime Therapeutics and will be denied).

    Change summary & material impact

    revised

    Commercial GLP-1 prior authorization criteria were updated to require clinical documentation of a type 2 diabetes diagnosis and documentation that the patient has tried and failed metformin, metformin combination drugs, or insulin; requests lacking this documentation will be denied.

    Effective Jan 1, 2024clarifiedLatest

    Florida Blue clarified GLP-1 coverage is limited to FDA‑approved indications for treatment of type 2 diabetes; medications for weight loss/management (e.g., Wegovy, Saxenda) are excluded and some commercial and Medicare members will no longer be covered starting January 1, 2024 if they do not meet policy guidelines.

    This is a material change that increases documentation requirements and will result in denials if not met; providers must submit clinical documentation of a type 2 diabetes diagnosis and evidence of prior trial/failure of metformin, metformin combination drugs, or insulin. Additionally, some commercial and Medicare members will no longer be covered for GLP‑1 drugs starting January 1, 2024 if they do not meet the updated policy guidelines, and weight‑loss/management uses (e.g., Wegovy, Saxenda) are excluded from coverage.

    Effective dates and immediate actions

    Effective date and actions
    Effective dateJan 1, 2024
    Key actionSubmit required clinical documentation with PA: include documentation of type 2 diabetes diagnosis and prior trial/failure of metformin/metformin combinations or insulin
    Key actionDo not submit requests for weight-loss/management indications (eg, Wegovy, Saxenda); these will be denied and must be paid OOP
    Key actionUse Prime Therapeutics and CoverMyMeds to submit PA requests and follow GLP-1 prior authorization questions at myPrime.com
    Denial Risk

    Missing required documentation or off‑label indications will lead to denials

    Commercial GLP‑1 prior authorization criteria were updated to require clinical documentation of type 2 diabetes diagnosis and documentation of prior trial/failure of metformin/metformin combinations or insulin.

    Policy Summary
    PayerFlorida Blue
    Policyproviders-news-2023-pharmacy-glp-1-drugs-11-2023.pdf
    Policy CodePolicy N/A
    Change TypeCoverage & prior authorization criteria revised
    Effective Date
    Next Review Date
    Key ActionProviders must include clinical documentation of a type 2 diabetes diagnosis and document prior trial/failure of metformin/metformin combos or insulin with GLP‑1 prior authorization requests; requests lacking this documentation will be denied.
    SourceLink
    On This Page
    What changed — quick summaryCoverage criteria and denial conditionsCovered and excluded GLP‑1 drugs (examples)What providers must doDefinitions and scope notesChange summary & material impactEffective dates and immediate actions

    Authorization requests will be denied when ANY of the following apply:

    ANY of the following

    • Off‑label/not FDA‑approved indication: Indication is off‑label or not an FDA‑approved indication for type 2 diabetes (including weight loss/management).
    • Missing diagnosis documentation: Provider fails to provide clinical documentation of a type 2 diabetes diagnosis.
    • Missing prior therapy documentation: Provider fails to document prior trial and failure of metformin, metformin combination drugs, or insulin when required by prior authorization criteria.

    Requests for GLP‑1 medications for weight loss/management (including Wegovy, Saxenda, or similar) will be denied and should not be submitted to Prime Therapeutics; patients must pay out-of-pocket if pursued.

    • Wegovy
    • Saxenda
    Documentation Required

    Reference prior authorization questions

    Providers should use the GLP‑1 prior authorization criteria questions available at myPrime.com and submit required documentation through Prime Therapeutics/CoverMyMeds per Florida Blue guidance.

    • Submit prior authorization requests via Prime Therapeutics/CoverMyMeds
    • Reference GLP‑1 prior authorization questions at myPrime.com